Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic
Open Access
- 17 August 2020
- journal article
- review article
- Published by Springer Nature in Journal of Neurology
- Vol. 268 (5) , 1580-1591
Abstract
The novel Coronavirus disease-19 (COVID-19) pandemic has posed several challenges for neuromuscular disorder (NMD) patients. The risk of a severe course of SARS-CoV-2 infection is increased in all but the mildest forms of NMDs. High-risk conditions include reduced airway clearance due to oropharyngeal weakness and risk of worsening with fever, fasting or infection Isolation requirements may have an impact on treatment regimens administered in hospital settings, such as nusinersen, glucosidase alfa, intravenous immunoglobulin, and rituximab infusions. In addition, specific drugs for SARS-CoV2 infection under investigation impair neuromuscular function significantly; chloroquine and azithromycin are not recommended in myasthenia gravis without available ventilatory support and prolonged prone positioning may influence options for treatment. Other therapeutics may affect specific NMDs (metabolic, mitochondrial, myotonic diseases) and experimental approaches for Coronavirus disease 2019 may be offered “compassionately” only after consulting the patient’s NMD specialist. In parallel, the reorganization of hospital and outpatient services may change the management of non-infected NMD patients and their caregivers, favouring at-distance approaches. However, the literature on the validation of telehealth in this subgroup of patients is scant. Thus, as the first wave of the pandemic is progressing, clinicians and researchers should address these crucial open issues to ensure adequate caring for NMD patients. This manuscript summarizes available evidence so far and provides guidance for both general neurologists and NMD specialists dealing with NMD patients in the time of COVID-19.Keywords
This publication has 94 references indexed in Scilit:
- Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus InfectionAnnals of Internal Medicine, 2014
- Prolonged Corrected QT Interval in Patients with Myotonic Dystrophy Type 1Journal of Clinical Neurology, 2013
- Rhabdomyolysis in An HIV-Infected Patient with Impaired Renal Function Concomitantly Treated with Rosuvastatin and Lopinavir/RitonavirAntiviral Therapy, 2010
- Complications of anaesthesia in neuromuscular disordersNeuromuscular Disorders, 2005
- Neuromuscular Disorders in Severe Acute Respiratory SyndromeArchives of Neurology, 2004
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004
- Control Measures for Severe Acute Respiratory Syndrome (SARS) in TaiwanEmerging Infectious Diseases, 2003
- Case Report: Drug-Induced Rhabdomyolysis after Concomitant Use of Clarithromycin, Atorvastatin, and Lopinavir/Ritonavir in a Patient with HIVAIDS Patient Care and STDs, 2003
- Chloroquine neuromyotoxicityThe American Journal of Medicine, 1988
- Antihistaminics, local anesthetics, and other amines as antiviral agents.Proceedings of the National Academy of Sciences, 1981